Skybiotech Healthcare Limited
Incorporated in 1983, Skybiotech Healthcare Ltd is in the business of Textile and Pharmaceuticals[1]
- Market Cap ₹ 35.6 Cr.
- Current Price ₹ 186
- High / Low ₹ 237 / 116
- Stock P/E
- Book Value ₹ 41.8
- Dividend Yield 0.00 %
- ROCE -9.32 %
- ROE -13.2 %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 4.45 times its book value
- Company has low interest coverage ratio.
- Company might be capitalizing the interest cost
- Debtor days have increased from 39.5 to 57.1 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Consumer Discretionary Textiles Textiles & Apparels Other Textile Products
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| 0.00 | 6.96 | 7.10 | |
| 0.12 | 9.21 | 8.58 | |
| Operating Profit | -0.12 | -2.25 | -1.48 |
| OPM % | -32.33% | -20.85% | |
| 2.00 | 0.38 | 0.31 | |
| Interest | 0.00 | 0.01 | 0.02 |
| Depreciation | 0.00 | 0.54 | 0.48 |
| Profit before tax | 1.88 | -2.42 | -1.67 |
| Tax % | 18.09% | -2.07% | -32.93% |
| 1.54 | -2.37 | -1.12 | |
| EPS in Rs | 8.04 | -12.38 | -5.85 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 2% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 53% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 46% |
| 3 Years: | 2% |
| 1 Year: | 11% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | -13% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Equity Capital | 1.92 | 1.92 | |
| Reserves | 7.07 | 6.08 | |
| 7.20 | 8.42 | ||
| 3.91 | 3.02 | ||
| Total Liabilities | 20.10 | 19.44 | |
| 12.03 | 11.55 | ||
| CWIP | 0.00 | 0.00 | |
| Investments | 2.46 | 2.24 | |
| 5.61 | 5.65 | ||
| Total Assets | 20.10 | 19.44 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| -1.04 | -1.52 | ||
| -9.63 | 0.02 | ||
| 1.24 | 1.17 | ||
| Net Cash Flow | -9.43 | -0.33 | |
| Free Cash Flow | -1.37 | -1.52 | |
| CFO/OP | 46% | 103% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Debtor Days | 22.03 | 57.06 | |
| Inventory Days | 74.68 | ||
| Days Payable | 79.35 | ||
| Cash Conversion Cycle | 22.03 | 52.40 | |
| Working Capital Days | -18.88 | -1.03 | |
| ROCE % | -9.32% |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Value of Quoted Investments INR ・Standalone data |
|
||||||||||
| Domestic Pharmaceutical Sales INR Lakhs |
|||||||||||
| Export Pharmaceutical Sales INR Lakhs |
|||||||||||
| Job Work Revenue (Pharmaceutical) INR Lakhs |
|||||||||||
| Pharmaceutical Subsidiary Revenue (Consolidated) INR Lakhs |
|||||||||||
| Equity Stake in Skybiotech Lifesciences Percentage ・Standalone data |
|||||||||||
Extracted by Screener AI
Documents
Announcements
-
Results Financials For The Year Ended On 31St March 2026
30 May - Board approved audited standalone and consolidated results for quarter and year ended 31 March 2026.
-
Board Meeting Outcome for Submission Of Outcome Of Board Meeting And Submission Of Financial Results For The Quarter And Year Ended On 31St March 2026
30 May - Board approved audited standalone and consolidated results for quarter and year ended 31 March 2026.
-
Board Meeting Intimation for Approval Of Audited Results For The Quarter And Year Ended On March 31, 2026
26 May - Board meeting on 30 May 2026 to approve audited financial results for quarter and year ended 31 March 2026.
-
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
30 Apr - Confirmed non-applicability of SEBI Large Corporate norms as of March 31, 2026.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
9 Apr - Regulation 74(5) certificate filed for quarter ended 31 March 2026; no physical shares received for demat.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2008
from bse
-
Financial Year 2007
from bse
-
Financial Year 2002
from bse
Business Overview:[1]
SBHCL was engaged in the Textile business and was not generating any revenue from its main business activity. It acquired 72.52% stake in M/s. Skybiotech Lifescience Private Limited which become their subsidiary and is engaged in manufacturing Pharmaceutical Products and ingredients